Correspondence Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies

被引：15
|
作者：
Maglione, Alessandro [1 ]
Morra, Marta [1 ]
Meroni, Raffaella [1 ]
Matta, Manuela [1 ]
Clerico, Marinella [1 ]
Rolla, Simona [1 ]
机构：
[1] Univ Turin, Dept Clin & Biol Sci, Turin, Italy
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2022年 / 61卷
关键词：
Multiple sclerosis; Anti-SARS-Cov2; vaccine; Booster; Third dose;
D O I：
10.1016/j.msard.2022.103776
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Anti-SARS-CoV2 mRNA vaccines showed a blunted antibody (Ab) response in people with MS (pwMS) on high efficacy therapies, suggesting the need for a booster dose. We evaluated the kinetics of the production of antireceptor binding domain (RBD) Immunoglobulins G (IgG) after the vaccination cycle and the booster in pwMS receiving ocrelizumab, fingolimod and cladribine. A significant increase of anti-RBD IgG seroconversion was observed after booster respect to the vaccination cycle. Results obtained from this study will be useful for the management of pwMS in relation to their disease modifying therapy (DMT) and for any future vaccination campaign.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Petereit, Hela-Felicitas
    Tumani, Hayrettin
    Zettl, Uwe K.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [2] Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Piquet, Amanda L.
    Corboy, John R.
    Vollmer, Timothy L.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [3] Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Achiron, Anat
    Mandel, Mathilda
    Dreyer-Alster, Sapir
    Harari, Gil
    Magalashvili, David
    Sonis, Polina
    Dolev, Mark
    Menascu, Shay
    Flechter, Shlomo
    Falb, Rina
    Gurevich, Michael
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [4] Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Achiron, Anat
    Mandel, Mathilda
    Dreyer-Alster, Sapir
    Harari, Gil
    Magalashvili, David
    Sonis, Polina
    Dolev, Mark
    Menascu, Shay
    Flechter, Shlomo
    Falb, Rina
    Gurevich, Michael
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [5] Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article
    Barriere, Jerome
    Carles, Michel
    Audigier-Valette, Clarisse
    Re, Daniel
    Adjtoutah, Zoubir
    Seitz-Polski, Barbara
    Gounant, Valerie
    Descamps, Diane
    Zalcman, Gerard
    EUROPEAN JOURNAL OF CANCER, 2022, 162 : 182 - 193
  • [6] Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients
    Benitez Fuentes, Javier David
    Mohamed Mohamed, Kauzar
    de Luna Aguilar, Alicia
    Jimenez Garcia, Carlos
    Guevara-Hoyer, Kissy
    Fernandez-Arquero, Miguel
    Rodriguez de la Pena, M. Antonia
    Garciia Bravo, Laura
    Jimenez Ortega, Alejandro Francisco
    Flores Navarro, Paloma
    Bartolome Arcilla, Jorge
    Alonso Arenilla, Barbara
    Baos Munoz, Elvira
    Delgado-Iribarren Garcia-Campero, Alberto
    Montealegre Sanz, Maria
    Sanchez-Ramon, Silvia
    Perez Segura, Pedro
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis
    Maglione, Alessandro
    Francese, Rachele
    Arduino, Irene
    Rosso, Rachele
    Matta, Manuela
    Rolla, Simona
    Lembo, David
    Clerico, Marinella
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [8] Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies
    Maniscalco, Giorgia Teresa
    Liotti, Antonietta
    Ferrara, Anne Lise
    Prestipino, Elio
    Salvatore, Simona
    Di Battista, Maria Elena
    Moreggia, Ornella
    Cesare, Daniele Di Giulio
    Vastano, Roberta
    Belardo, Martina
    Napolitano, Massimo
    Ranieri, Angelo
    Longo, Katia
    Andreone, Vincenzo
    De Rosa, Veronica
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [9] Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies
    Maniscalco, Giorgia Teresa
    Liotti, Antonietta
    Ferrara, Anne Lise
    Prestipino, Elio
    Salvatore, Simona
    Di Battista, Maria Elena
    Moreggia, Ornella
    Cesare, Daniele Di Giulio
    Vastano, Roberta
    Belardo, Martina
    Napolitano, Massimo
    Ranieri, Angelo
    Longo, Katia
    Andreone, Vincenzo
    De Rosa, Veronica
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [10] Performance of treatment response scoring systems among patients with multiple sclerosis treated with high-efficacy therapies
    Marrodan, Mariano
    Sao Aviles, Augusto
    Rio, Jordi
    Cobo-Calvo, Alvaro
    Fernandez, Victoria
    Pappolla, Agustin
    Castillo, Joaquin
    Vidal-Jordana, Angela
    Arrambide, Georgina
    Tur, Carmen
    Rodriguez-Acevedo, Breogan
    Zabalza, Ana
    Mongay-Ochoa, Neus
    Vilaseca, Andreu
    Rodriguez, Marta
    Galan, Ingrid
    Comabella, Manuel
    Sastre-Garriga, Jaume
    Tintore, Mar
    Auger, Cristina
    Rovira, Alex
    Montalban, Xavier
    Midaglia, Luciana
    MULTIPLE SCLEROSIS JOURNAL, 2025, : 568 - 577
12345